Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Taking advantage of drug resistance, a new approach in the war on cancer

Open access
Wang, Liqin, Bernards, Rene · 2018 · Frontiers of Medicine

Abstract

Identification of the driver mutations in cancer has resulted in the development of a new category of molecularly targeted anti-cancer drugs. However, as was the case with conventional chemotherapies, the effectiveness of these drugs is limited by the emergence of drug-resistant variants. While most cancer therapies are given in combinations that are designed to avoid drug resistance, we discuss here therapeutic approaches that take advantage of the changes in cancer cells that arise upon development of drug resistance. This approach is based on notion that drug resistance comes at a fitness cost to the cancer cell that can be exploited for therapeutic benefit.We discuss the development of sequential drug therapies in which the first therapy is not given with curative intent, but to induce a major new sensitivity that can be targeted with a second drug that selectively targets the acquired vulnerability. This concept of collateral sensitivity has hitherto not been used on a large scale in the clinic and holds great promise for future cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11684-018-0647-7

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 53

Metadata

Authors
Wang, L., & Bernards, R.
Affiliations
The Netherlands Cancer Institute (NL)
Venue
Frontiers of Medicine
Published
2018-07-18
Volume
12
Issue
4
Pages
490-495
ISSN
  • 1673-7342 (ISSN-L)
  • 2095-0217
  • 2095-0225
OpenAlex
W2884677532
Cited by
53
References
32
Citations by year
2026: 1 · 2025: 10 · 2024: 7 · 2023: 7 · 2022: 13 · 2021: 6 · 2020: 3 · 2019: 5 · 2018: 1
FWCI
2.86
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Frontiers of Medicine (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • KWF Kankerbestrijding
  • Oncode Institute
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
drug resistance, collateral sensitivity, acquired drug resistance, molecularly targeted cancer therapy, fitness cost, cancer cell adaptation, combination therapy
MeSH terms
Pharmacogenomic Testing, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Neoplasm, Therapies, Investigational, Medication Therapy Management, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Taking advantage of drug resistance, a new approach in the war on cancer. https://app.cochat.ai/papers/10.1007/s11684-018-0647-7
The paper
Wang, L., & Bernards, R. (2018). Taking advantage of drug resistance, a new approach in the war on cancer. Frontiers of Medicine. https://doi.org/10.1007/s11684-018-0647-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.